Bioconjugation services for molecular Imaging

Molecular imaging tools can speed-up the evaluation of drug candidates. SPECT/PET or optical in vivo imaging requires the injection of a labeled molecule, containing an imaging probe and a targeting vehicle, designed to  interact with a biological target. The development of such agent is often not straightforward and can be a rate-limiting step in molecular imaging.

Welience Bioconjugates brings its expertise to identify the best strategy for labeling a biomolecule for imaging studies.

OUR SERVICES INCLUDE :  

• Modification of antibodies, antibody fragments (Fab, Fab’, Fab’2, ScFv, Nanobody, Affibody) or other biologics with chelators (DOTA, DOTAGA, NODAGA or DFO-like compounds) or with fluorescent dyes adapted for in vivo optical  imaging
 - Optimization of Degree of Labeling (DOL)
 - Purification and quantification included in the process

• Development of radiolabeling procedures (Cu64, In111, Ga68, Zr89, Lu177, Y90)
 - Quality Control: Radiochemical purity, radiolabeling yield  assessed by radio-HPLC and/or radio-ITLC.
 - Stability tests in serum or others biological media. 

• Synthesis of peptide-based conjugates for in vivo or in vitro imaging;

•Preparation of multimodal probes for fluorescence imaging and/or nuclear imaging, and /or MRI.

COMPETITIVE ADVANTAGES

• Customized conjugation solutions;
• A deep knowledge and rich experience in the design and synthesis of imaging probes and radioconjugates;
• Global offer: from chemistry to in vivo imaging (easy access to a fully equipped preclinical imaging platform).
  

APPLICATIONS/MARKETS

• Drug discovery:
 - Drug biodistribution monitoring;

 - Pharmaco-imaging studies;

• Preclinical proof-of-concept;
• Image guided therapy and surgery;
• Imaging biomarker;
• RadioImmunoTherapy (RIT).

LABORATORY

Institut de Chimie Moléculaire de l’Université de Bourgogne (ICMUB).

CONTACT 

Ludmila Monteiro

Development manager

Tel.: +33 (0)6.31.10.21.21

Mail: ludmila.monteiro@sattge.fr